|
Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study). |
| |
|
No Relationships to Disclose |
| |
|
Travel, Accommodations, Expenses - Chugai Pharma Europe |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche |
| |
|
Consulting or Advisory Role - Roche |
Travel, Accommodations, Expenses - Roche |
| |
|
No Relationships to Disclose |
| |
|
Speakers' Bureau - Bristol-Myers Squibb; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |